NM_080390.4(TCEAL2):c.160G>A (p.Val54Ile) AND not specified

Germline classification:: Uncertain significance (1 submission)
Last evaluated:: Dec 15, 2023
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV004466381.1

Allele description [Variation Report for NM_080390.4(TCEAL2):c.160G>A (p.Val54Ile)]

NM_080390.4(TCEAL2):c.160G>A (p.Val54Ile)

Gene:

TCEAL2:transcription elongation factor A like 2 [Gene - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

Xq22.1

Genomic location:

Preferred name:

NM_080390.4(TCEAL2):c.160G>A (p.Val54Ile)

HGVS:

NC_000023.11:g.102126990G>A
NG_012818.1:g.6303G>A
NM_080390.4:c.160G>AMANE SELECT
NP_525129.1:p.Val54Ile
NC_000023.10:g.101381962G>A
NM_080390.3:c.160G>A

Protein change:

V54I

Molecular consequence:

NM_080390.4:c.160G>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Synonyms:: AllHighlyPenetrant
Identifiers:: MedGen: CN169374

Recent activity

Clear Turn Off Turn On

hypothetical protein TSTA_104950 [Talaromyces stipitatus ATCC 10500]
hypothetical protein TSTA_104950 [Talaromyces stipitatus ATCC 10500]
gi|218714858|gb|EED14281.1||gnl|WGS |cds.TSTA_104950A

Protein
beta-fibrinogen, partial [Colobosaura modesta]
beta-fibrinogen, partial [Colobosaura modesta]
gi|1835287808|gb|QJE63399.1|

Protein
cytochrome b, partial (mitochondrion) [Colobosaura modesta]
cytochrome b, partial (mitochondrion) [Colobosaura modesta]
gi|1835287704|gb|QJE63347.1|

Protein
matrix remodeling associated 5, partial [Colobosaura modesta]
matrix remodeling associated 5, partial [Colobosaura modesta]
gi|1835287582|gb|QJE63286.1|

Protein
Mus musculus refilin B (Rflnb), mRNA
Mus musculus refilin B (Rflnb), mRNA
gi|268370104|ref|NM_029658.1|

Nucleotide

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV004961925	Ambry Genetics	criteria provided, single submitter (Ambry Variant Classification Scheme 2023)	Uncertain significance (Dec 15, 2023)	germline	clinical testing	Citation Link

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV004961925

Ambry Genetics

criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)

Uncertain significance
(Dec 15, 2023)

germline

clinical testing

Citation Link

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Details of each submission

From Ambry Genetics, SCV004961925.1

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	not provided

Description

The c.160G>A (p.V54I) alteration is located in exon 3 (coding exon 1) of the TCEAL2 gene. This alteration results from a G to A substitution at nucleotide position 160, causing the valine (V) at amino acid position 54 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: May 7, 2024

ClinVar

Relating variation to medicine